Toronto Dominion Bank’s Cardiff Oncology CRDF Stock Holding History

Toronto Dominion Bank’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4	Closed	–	–	1425
2022 Q1	$0	Hold	4	–	–	﹤0.01%	1520
2021 Q4	$0	Buy	+4	New	+$24	﹤0.01%	1585

Other funds holding CRDF

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Toronto Dominion Bank's CRDF Position: Q2 2022 in Review

Toronto Dominion Bank sold out of Cardiff Oncology (CRDF) in Q2 2022, closing a stake of 4 shares.

Toronto Dominion Bank first reported a position in CRDF in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 67 funds tracked by Wall St. Rank hold CRDF as of Q2 2022.

Toronto Dominion Bank reported no remaining Cardiff Oncology position as of Q2 2022 after selling out during the quarter.
Toronto Dominion Bank sold 4 Cardiff Oncology shares in Q2 2022.
Toronto Dominion Bank first reported a position in Cardiff Oncology in Q4 2021 and held it in 2 quarters.
Toronto Dominion Bank's Cardiff Oncology position peaked at $0 in Q1 2022.
67 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2022.

Based on Toronto Dominion Bank's 13F filing for Q2 2022, filed 11 Aug 2022.